SU1674847A1 - Method for treatment of inflammatory bronchopulmonary diseases - Google Patents

Abstract

This invention relates to medicine, in particular to pulmonology. The goal is to reduce the duration of treatment, lengthen the remission of the disease by stimulating the repair of the pulmonary epithelium and the function of the mucociliary apparatus. To this end, bemithyl is additionally introduced into the known complex treatment of the disease, including immunocorrective agents. This makes it possible to significantly reduce the time of treatment of the exacerbation of the process, by 1.5 times lengthening the remission of the disease.

Description

This invention relates to medicine, in particular to pulmonology.

The purpose of the invention is to reduce the treatment time, lengthen the remission period of the disease by stimulating the regeneration of the pulmonary epithelium and the function of the mucociliary apparatus,

The method is carried out as follows.

According to indications, patients with inflammatory diseases of the lungs are given antibiotics and sulfonamides taking into account the sensitivity of the pathogen, as well as bronchodilatory, expectorant drugs and immunocorrective drugs. Along with this, an additional agent of the act-protectors group is administered - bemitil, which is prescribed after a meal in O J5 - 1.0 g per day for 6-8 days. During the period of taking bemittil, a diet rich in carbohydrates is provided. In the absence or weak positive effect, determined by the indicators of mucociliary clearance and the dynamics of the clinical

during the pathological process, the use of the drug can be repeated according to the indicated scheme.

Example 1. Patient A. was in the pulmonary department because of the exacerbation of chronic bronchitis. Treatments before admission to the clinic is outpatient, but without effect. Due to deterioration, he was hospitalized in the hospital. On admission, the patient had complaints of cough with a moderate amount of mucus-purulent sputum, low-grade fever, weakness, sweating. In the lungs, scattered dry rales were heard against the background of hard breathing. On radiographs of the chest - the deformation of the pulmonary pattern of a fat character. In a spirographic study, moderate restrictive ventilation disorders were recorded. The endoscopic picture in fibrobronchoscopy indicated the presence of signs of pronounced bilateral diffuse catarrhal endobronchitis. Blood leukocytosis was observed.

VI

.N

with

4 XI

Toz (up to 12,000), as well as accelerated ESR (up to 19 mm / h). Patients, along with treatment with antibiotics and sulfa drugs, as well as bronchodilator and expectorant drugs with endobronchial administration of prodigiosan, were prescribed 0.25 g of boehmil 3 times a day after meals. During the period of treatment with bomitil, a meal rich in carbohydrates was provided. On the background of the therapy, the patient underwent clinical, laboratory and instrumental research methods, which indicated a relatively rapid reverse development of the pathological process. On the 9th day from the moment of admission, the patient began to go into remission and the patient was discharged from the clinic in a satisfactory condition. Subsequent observation of the patient for 1 year indicated a normal condition of the patient who felt good and did not present any complaints, whereas during the previous year the patient had repeatedly exacerbated the disease.

Example 2. Patient S. was in the clinic for an exacerbation of bronchiectasis. On admission, there were complaints of pronounced cough with the separation of a large amount of mucus-purulent, purulent character, low-grade fever, weakness, sweating. During auscultation of the left, in the lower parts, rales of different caliber were heard, and for the rest of the time, scattered dry rales were heard. X-ray examination shows a deformity of the pulmonary pattern in the cellular type, mainly in the lower lobe of the left lung, which is reduced in volume. Spirographic indicators indicated the presence of high-quality obstructive and moderate restrictive signs of impaired lung ventilation capacity. At fibrobronchoscopy, signs of restrictive purulent endobronchitis in the bronchi of the lower lobe of the left lung, as well as bilateral diffuse catarrhal endobronchitis were revealed. General and biochemical blood tests reflected the presence of chronic inflammatory activity.

The patient was prescribed treatment with antibiotics and sulfa drugs, as well as bronchodilatory and expectorant drugs and endobronchial immunocorrective therapy with prodigiosan. In addition, the patient was additionally prescribed boemitil in a daily dose of 1 g for 7 days. Through

11 days after the start of treatment, the patient had no complaints, auscultation - no rales in the lungs were heard, spirography normalized, there was

the dynamics of the endoscopic picture in the fibrobronscopic examination is significantly positive, i.e. There was a remission of the disease. Follow-up of the patient for

0 1 year indicated that the remission of the process was maintained throughout the entire observation period, whereas during the previous year the patient had been temporarily disabled for more than 2 months.

5 Taking into account that mucociliary clearance is due to the function of the epithelium of the mucous membrane of the respiratory tract, and therefore reflects its condition and characterizes the regenerative processes in it, from which it

0 significantly depends, were carried out in the dynamics of the study of mucociliary clearance by the radio aerosol method against the background of the treatment of COPD by means of the known and known methods for the evaluation of their effectiveness. A comparative assessment of the research results indicates that using the inventive method results in higher muciliary clearance, i.e. it provides a more efficient restoration of the functional state of the respiratory tract mucosa.

Analysis of the effectiveness of therapy has shown that using the proposed method

5 also achieves a more rapid therapeutic effect than as a result of applying a known method. The method is successfully used for acute pneumonia. A comparative analysis of treatment terms for each disease revealed statistically significant differences, which also indicate a significant reduction in the duration of treatment. Thus, in the treatment of chronic bronchitis according to the method

5, the average term was 11, 8 days, whereas in a known manner - 17.9 days (p 0.05). The treatment of patients with bronchiectatic disease in a known manner was also significantly longer than 22.7 days, than

0 for the time - 15.1 days.

Subsequent observation of patients for a period of 1 year showed that with the help of the treatment by the inventive method, in comparison with the known method, it was possible to reduce the number of

5 exacerbations of the disease (1.6 times), as well as terms of temporary disability (1.7 times) and significantly lengthen the remission of the disease.

Thus, the claimed method makes it possible to reduce the duration of treatment, the number of

and lengthen the remission of chronic complex therapy, including immunospecific lung diseases.

The method is simple to perform and can shi-what, in order to shorten the treatment time,

It is used in clinical practice for prolonging disease remission due to

ke.5 stimulating the regeneration of the pulmonary epithelium formula of the invention and the function of the mucociliary apparatus

A method of treating inflammatory broncho-immunocorrectors is administered in combination with a non-pulmonary disease by conducting mytil.

Claims (1)

The claims The method of treatment of inflammatory bronchopulmonary diseases by conducting complex therapy, including immunocorrections. characterized in that, in order to reduce the duration of treatment, to prolong the remission of the disease by stimulating the regeneration of the pulmonary epithelium and the function of the mucociliary apparatus, immunocorrections are administered in combination with bemitil.